What Happened to Candida auris?

Candida auris, a species of yeast, first garnered significant attention after its official description in Japan in 2009, isolated from a patient's ear canal. However, retrospective analyses later revealed earlier isolates from South Korea dating back to 1996, initially misidentified as other Candida species. This initial misidentification highlighted a key challenge in its detection, as standard laboratory methods often failed to correctly identify C. auris, leading to delayed infection control measures and further spread.

The fungus's global emergence was characterized by its simultaneous and independent appearance in multiple regions, including South Asia, South Africa, South America, and East Asia, suggesting a rapid, parallel evolution rather than a single point of origin. By the mid-2010s, C. auris had spread across Asia and Europe, reaching the United States by 2013. Its ability to cause invasive candidiasis, infecting the bloodstream, central nervous system, and internal organs, coupled with its high mortality rate of 30-60% in cases of bloodstream infections, quickly elevated it to a critical public health concern.

A major turning point in the C. auris narrative is its inherent and acquired multidrug resistance. A significant percentage of isolates are resistant to azoles (like fluconazole), and resistance to amphotericin B and echinocandins has also been observed, with some strains exhibiting pan-resistance to all three major classes of antifungal drugs. This resistance complicates treatment, often requiring combinations of antifungals or newer, pre-approved drugs. The COVID-19 pandemic further accelerated its spread, as healthcare systems faced unprecedented strain, leading to breakdowns in infection prevention protocols and increased use of invasive medical devices, which are known risk factors for C. auris infections.

As of 2026, Candida auris remains a persistent and growing threat, particularly in healthcare facilities such as hospitals and long-term care settings. The Centers for Disease Control and Prevention (CDC) continues to report significant increases in cases. For instance, a CDC report in early July 2026 noted annual increases between 2022 and 2024, with 2,882 cases in 2022, 4,428 in 2023, and 6,197 in 2024. By August 4, 2026, over 3,000 cases had been reported in 23 U.S. states for the year, with Texas, Michigan, and Illinois reporting the highest numbers. In January 2026, Missouri reported 757 additional cases between July 2024 and November 2025 across various healthcare facilities. The fungus was also reclassified based on genomic taxonomy as Candidozyma auris in 2024, though public health authorities often continue to use the original name.

The current status underscores the ongoing challenges: C. auris can colonize patients without causing symptoms, making detection difficult, and it can persist on inanimate surfaces for weeks, facilitating its spread through contaminated equipment and direct contact. Prevention relies heavily on meticulous infection control measures, including rigorous hand hygiene, isolation of infected or colonized patients, and thorough environmental cleaning with EPA-registered disinfectants effective against C. auris. Research continues into novel antifungal agents and diagnostic tools to combat this resilient pathogen.